Overview: Ceruloplasmin (Cerulo) TestIntroduction: The Ceruloplasmin Test measures ceruloplasmin to diagnose Wilson's disease or copper metabolism issues, causing liver or neurological symptoms. Aligned with 2023 AASLD guidelines, it uses spectrophotometry for high sensitivity, aiding in metabolic screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in biochemistry for patients with suspected copper disorders.
Other Names: Ceruloplasmin Assay, Copper Metabolism Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Ceruloplasmin testing began in the 1950s with Wilson's disease research. Spectrophotometry emerged in the 1970s, and by the 2000s, automated analyzers improved accuracy.
Purpose: Diagnoses Wilson's disease or copper metabolism issues, guides treatment, and monitors ceruloplasmin levels in patients with liver or neurological symptoms.
Test Parameters: 1. Ceruloplasmin
Pretest Condition: Fasting for 10-12 hours required to stabilize ceruloplasmin levels. Collect serum or plasma after overnight fasting. Report symptoms like liver dysfunction or tremors, and list medications like chelating agents.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document liver dysfunction, neurological symptoms, or family history of Wilson's disease. Include current medications, especially chelating agents or zinc.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for copper-lowering therapy.
Procedural Considerations: Uses spectrophotometry to measure ceruloplasmin levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Non-fasting samples or inflammation may alter results. Hemolysis or improper storage can degrade samples.
Clinical Significance: Low ceruloplasmin levels confirm Wilson's disease, prompting chelation therapy. Normal levels suggest alternative diagnoses.
Specialist Consultation: Consult a hepatologist for result interpretation. A neurologist referral is advised for neurological symptoms.
Additional Supporting Tests: 24-hour urine copper test, liver biopsy, or genetic testing to confirm Wilson's disease.
Test Limitations: False negatives may occur with inflammation. Results require clinical correlation with copper studies.
References: AASLD Wilson's Disease Guidelines, 2023; Hepatology, Roberts EA, 2022.
